Clinical Trials

Multiple clinical trials evaluate the pharmacokinetic properties and therapeutic applications of zolmitriptan across Early Phase 1, Phase 1, and Phase 4 studies. Sponsored by industrial, academic, and governmental entities—including AstraZeneca, Parc de Salut Mar, the FDA, the University of Kentucky, and NIDA—these studies assess migraine, cocaine use disorder, and healthy volunteers. Investigational efforts encompass both completed trials, such as post-marketing 5-HT1B receptor occupancy PET studies and pharmacokinetic modeling, and actively recruiting early-phase behavioral evaluations.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06074016 Completed
Healthy
Parc de Salut Mar|Food and Drug Administration (FDA)
 2023-07-12 Phase 1
NCT05019430 Recruiting
Cocaine Use Disorder
William Stoops|National Institute on Drug Abuse (NIDA)|University of Kentucky
 2021-10-15 Early Phase 1
NCT01085123 Completed
Migraine
AstraZeneca
 2010-05 Phase 1
NCT00637286 Completed
Migraine
AstraZeneca
 2004-07 Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Zolmitriptan product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Zolmitriptan selectively binds to and activates serotonin 5-HT1B and 5-HT1D receptors, which suppresses adenylate cyclase activity and reduces intracellular cyclic AMP levels to trigger vasoconstriction of dilated cranial blood vessels and inhibit neuropeptide release from trigeminal nerves. This targeted attenuation of neurogenic inflammation directly relieves acute vascular cephalic pain in migraine management and provides a clinical rationale for exploring serotonergic modulation in non-headache central nervous system disorders such as cocaine use disorder.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.